Sandoz launches direct-to-consumer platform with growth-hormone biosimilar Omnitrope
read at Endpoints ↗Positive
Sandoz announced a direct-to-consumer platform, initially offering Omnitrope, a biosimilar growth hormone for growth disorders.
The approach follows a trend among brand-name manufacturers to lower out-of-pocket costs by selling directly to patients, bypassing traditional distribution channels.
The platform currently features only this single drug, with Sandoz indicating it may add more products as the model is evaluated.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Sandoz launches direct-to-consumer platform with growth disorder drug”
read at Endpoints ↗81 words · retrieved Jul 2
comments(0)
5-min edit window · permanent after that